| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G |
| P698 | PubMed publication ID | 8174048 |
| P2093 | author name string | E Robinson | |
| N Haim | |||
| D Yarnitsky | |||
| R Epelbaum | |||
| M Ben-Shahar | |||
| W Simri | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2515-2519 | |
| P577 | publication date | 1994-05-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas | |
| P478 | volume | 73 |
| Q88543829 | A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314) |
| Q92865754 | Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review |
| Q52623821 | Autonomic nervous system and cancer. |
| Q47423347 | Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. |
| Q88812863 | Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes |
| Q43679244 | Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856. |
| Q40353559 | Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine |
| Q58794709 | Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome? |
| Q28547905 | G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound |
| Q37163738 | High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia |
| Q30366990 | Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. |
| Q40625823 | Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. |
| Q37662576 | Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. |
| Q35105053 | Neuromuscular complications of cancer |
| Q35187357 | Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management |
| Q81581465 | Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia |
| Q47599462 | Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. |
| Q91906354 | Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification |
| Q37114564 | The distinctive biology of cancer in adolescents and young adults. |
| Q27000078 | Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine |
| Q36967160 | Treatment of acute lymphoblastic leukaemia : a new era. |
| Q28078232 | Vincristine-induced peripheral neuropathy in pediatric cancer patients |
| Q33824948 | [EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect? |
Search more.